载透明质酸-甲基胶原-三元共聚物/多柔比星复合膜的钽支架的制备及处方优化
|
摘要
目的:制备载透明质酸-甲基胶原-三元共聚物(甲基丙烯酸羟乙酯-甲基丙烯酸甲酯-甲基丙烯酸)/多柔比星复合膜的钽支架,并优化处方。方法:以金属钽支架为载体,透明质酸、甲基胶原、三元共聚物为辅料,利用静电自组装反应制备复合膜。以1、30 d的累积释放度为指标,采用正交设计优化透明质酸、甲基胶原、三元共聚物的质量浓度并验证;考察其体外释药行为。结果:最优处方为透明质酸1 mg/ml、甲基胶原4.5 mg/ml、三元共聚物100 mg/ml;所制钽支架1、30 d的累积释放度分别为7.57%、84.14%,RSD分别为2.3%、2.1%(n=3),20 d后近似呈零级速率释药。结论:成功制得具有缓释功能的载透明质酸-甲基胶原-三元共聚物/多柔比星复合膜的钽支架。
OBJECTIVE: To prepare Hyaluronic acid-methyl collagen-terpolymer(HEMA-MMA-MAA)/Doxorubicin compound membranes-loaded tantalum stent,and to optimize the formulation. METHODS:Electrostatic self-assembly reaction was adopted to prepare compound membranes using metal tantalum stent as carrier,hyaluronic acid,methyl collagen and terpolymer as excipients. With 1 and 30 d accumulative release rate as index,orthogonal test was used to optimize mass concentrations of hyaluronic acid,methyl collagen and terpolymer,and validated. The drug release behavior in vitro were investigated. RESULTS:The optimal formulation was as hyaluronic acid 1 mg/ml,methyl collagen 4.5 mg/ml and terpolymer 100 mg/ml. 1 and 30 d accumulative release rates of prepared tantalum stent were 7.57%(RSD=2.3%,n=3)and 84.14%(RSD=2.1%,n=3),respectively. 20 d later,dissolution rate approximated to zero level rate of drug release. CONCLUSIONS:Hyaluronic acid-methyl collagen-terpolymer/Doxorubicin compound membranes-loaded tantalum stent with sustained-release property is prepared successfully.
OBJECTIVE: To prepare Hyaluronic acid-methyl collagen-terpolymer(HEMA-MMA-MAA)/Doxorubicin compound membranes-loaded tantalum stent,and to optimize the formulation. METHODS:Electrostatic self-assembly reaction was adopted to prepare compound membranes using metal tantalum stent as carrier,hyaluronic acid,methyl collagen and terpolymer as excipients. With 1 and 30 d accumulative release rate as index,orthogonal test was used to optimize mass concentrations of hyaluronic acid,methyl collagen and terpolymer,and validated. The drug release behavior in vitro were investigated. RESULTS:The optimal formulation was as hyaluronic acid 1 mg/ml,methyl collagen 4.5 mg/ml and terpolymer 100 mg/ml. 1 and 30 d accumulative release rates of prepared tantalum stent were 7.57%(RSD=2.3%,n=3)and 84.14%(RSD=2.1%,n=3),respectively. 20 d later,dissolution rate approximated to zero level rate of drug release. CONCLUSIONS:Hyaluronic acid-methyl collagen-terpolymer/Doxorubicin compound membranes-loaded tantalum stent with sustained-release property is prepared successfully.
引文
[1]王明,杨小平,苏宇雄,等.定量缓释基因重组碱性成纤维细胞生长因子/聚乳酸-聚羟基乙酸植入片的制备及体外释药研究[J].中华口腔医学研究杂志,2008,2(2):19.
[2]李勃,肖引,刘凯,等.阿霉素磁靶向药物制剂研究进展[J].中国药业,2014,23(10):96.
[3]屠锡德.药剂学[M].3版.北京:人民卫生出版社,2002:949-951.
[4]樊秋平,梁嘉碧,杨海云,等.热疗用阿霉素温敏纳米粒的制备及工艺优化[J].中国药房,2011,22(17):1 580.
[5]祝侠丽,贾永艳,黄海英,等.正交设计法优化布洛芬缓释骨架片的处方工艺[J].中国药房,2014,25(9):830.
[6]鲍玉成,张文龙,王勇,等.长效缓释双药物人工骨的制备及释放特性[J].中国组织工程研究,2012,16(38):7 126.
[7]陈建澎,王婧茜,易喻,等.透明质酸及其衍生物研究进展[J].中国生物工程杂志,2015,35(2):111.
[2]李勃,肖引,刘凯,等.阿霉素磁靶向药物制剂研究进展[J].中国药业,2014,23(10):96.
[3]屠锡德.药剂学[M].3版.北京:人民卫生出版社,2002:949-951.
[4]樊秋平,梁嘉碧,杨海云,等.热疗用阿霉素温敏纳米粒的制备及工艺优化[J].中国药房,2011,22(17):1 580.
[5]祝侠丽,贾永艳,黄海英,等.正交设计法优化布洛芬缓释骨架片的处方工艺[J].中国药房,2014,25(9):830.
[6]鲍玉成,张文龙,王勇,等.长效缓释双药物人工骨的制备及释放特性[J].中国组织工程研究,2012,16(38):7 126.
[7]陈建澎,王婧茜,易喻,等.透明质酸及其衍生物研究进展[J].中国生物工程杂志,2015,35(2):111.